Revenue
2019
2020
2021
2022
2023
2024
2025
Allogene Therapeutics, Inc. (ALLO)
Price$1.99Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22,000 | $95,000 | $156,000 | $114.1M | $0 | $0 | — |
| Research & development | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | $151.9M |
| Operating expenses | $209.3M | $273.2M | $327.8M | $335.7M | $294.3M | $258.2M | $202.0M | $192.8M |
| Operating income | −$209.3M | −$273.2M | −$327.7M | −$335.5M | −$180.2M | −$258.2M | −$202.0M | −$192.8M |
| Operating margin | — | −1,241,813.64% | −344,986.32% | −215,087.18% | −157.94% | — | — | — |
| EBITDA | −$197.0M | −$259.6M | −$313.5M | −$321.2M | −$169.7M | −$250.8M | −$197.4M | −$191.8M |
| EBITDA margin | — | −1,179,818.18% | −330,040.00% | −205,920.51% | −148.74% | — | — | — |
| Net income | −$190.9M | −$257.6M | −$327.3M | −$340.4M | −$182.1M | −$316.4M | −$184.6M | −$211.5M |
| Net profit margin | — | −1,170,863.64% | −344,489.47% | −218,214.10% | −159.57% | — | — | — |
| Basic EPSper basic share | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 | -$1.83 | -$7.31 |
| Diluted EPSper diluted share | -$0.87 | -$1.32 | -$2.09 | -$2.38 | -$1.34 | -$2.63 | -$1.83 | -$7.31 |
Owners
Reported shareholders
8.73%of listed shares
BlackRock, Inc.30.15M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 8.73%30.15M shares |
Frazier Life Sciences Management, L.P. | 6.50%22.45M shares |
Pfizer Inc | 6.38%22.03M shares |
STATE STREET CORP | 5.51%19.03M shares |
TPG GP A, LLC | 5.42%18.72M shares |
Sio Capital Management, LLC | 3.86%13.32M shares |
PRIMECAP MANAGEMENT CO/CA/ | 3.80%13.12M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.52%12.17M shares |
FMR LLC | 3.48%12.01M shares |
Belldegrun Arie | ≈3.19%11.01M shares |
CITADEL ADVISORS LLC | 2.92%10.09M shares |
Chang David D | ≈2.33%8.06M shares |
TWO SIGMA INVESTMENTS, LP | 2.25%7.78M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.04%7.05M shares |
GOLDMAN SACHS GROUP INC | 1.78%6.15M shares |
GordonMD Global Investments LP | 1.53%5.3M shares |
MARSHALL WACE, LLP | 1.48%5.1M shares |
Patient Square Capital LP | 1.46%5.05M shares |
Aberdeen Group plc | 1.45%5M shares |
MILLENNIUM MANAGEMENT LLC | 1.40%4.84M shares |
Percentages use 345.35M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2026Form 4 | Yoshiyama AnnieSVP, Finance | SellCommon Stock | 9.6K | $2.31 | $22.1K | 124.5K |
| Mar 31, 2026Form 4 | Beneski Benjamin MachinasSVP, Chief Technical Officer | SellCommon Stock | 2.9K | $2.50 | $7.2K | 195.3K |
| Mar 16, 2026Form 4 | Beneski Benjamin MachinasSVP, Chief Technical Officer | SellCommon Stock | 4.8K | $2.47 | $11.9K | 198.2K |
| Mar 16, 2026Form 4 | Chang David DPresident and CEO | SellCommon Stock | 47.8K | $2.47 | $118.0K | 5.15M |
| Mar 2, 2026Form 4 | Beneski Benjamin MachinasSVP, Chief Technical Officer | SellCommon Stock | 7.1K | $2.60 | $18.5K | 203.0K |